vs
MERCURY GENERAL CORP（MCY）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
MERCURY GENERAL CORP的季度营收约是Revvity的2.0倍（$1.5B vs $772.1M），MERCURY GENERAL CORP净利率更高（13.2% vs 12.7%，领先0.4%），MERCURY GENERAL CORP同比增速更快（12.4% vs 5.9%），MERCURY GENERAL CORP自由现金流更多（$273.9M vs $161.8M），过去两年MERCURY GENERAL CORP的营收复合增速更高（9.8% vs 9.0%）
水星通用集团是一家综合性保险机构，业务覆盖个人车险、房主保险、租客保险及商业保险等多个品类，其中车险与房主保险是公司的核心经营板块。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
MCY vs RVTY — 直观对比
营收规模更大
MCY
是对方的2.0倍
$772.1M
营收增速更快
MCY
高出6.6%
5.9%
净利率更高
MCY
高出0.4%
12.7%
自由现金流更多
MCY
多$112.1M
$161.8M
两年增速更快
MCY
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.5B | $772.1M |
| 净利润 | $202.5M | $98.4M |
| 毛利率 | 99.7% | — |
| 营业利润率 | 16.2% | 14.5% |
| 净利率 | 13.2% | 12.7% |
| 营收同比 | 12.4% | 5.9% |
| 净利润同比 | 100.4% | 3.9% |
| 每股收益（稀释后） | $3.66 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MCYRVTY
| Q4 25 | $1.5B | $772.1M | ||
| Q3 25 | $1.6B | $698.9M | ||
| Q2 25 | $1.5B | $720.3M | ||
| Q1 25 | $1.4B | $664.8M | ||
| Q4 24 | $1.4B | $729.4M | ||
| Q3 24 | $1.5B | $684.0M | ||
| Q2 24 | $1.3B | $691.7M | ||
| Q1 24 | $1.3B | $649.9M |
净利润MCYRVTY
| Q4 25 | $202.5M | $98.4M | ||
| Q3 25 | $280.4M | $46.7M | ||
| Q2 25 | $166.5M | $53.9M | ||
| Q1 25 | $-108.3M | $42.2M | ||
| Q4 24 | $101.1M | $94.6M | ||
| Q3 24 | $230.9M | $94.4M | ||
| Q2 24 | $62.6M | $55.4M | ||
| Q1 24 | $73.5M | $26.0M |
毛利率MCYRVTY
| Q4 25 | 99.7% | — | ||
| Q3 25 | 99.8% | 53.6% | ||
| Q2 25 | 99.8% | 54.5% | ||
| Q1 25 | 99.7% | 56.5% | ||
| Q4 24 | 99.7% | — | ||
| Q3 24 | 99.8% | 56.3% | ||
| Q2 24 | 99.8% | 55.7% | ||
| Q1 24 | 99.7% | 54.6% |
营业利润率MCYRVTY
| Q4 25 | 16.2% | 14.5% | ||
| Q3 25 | 22.1% | 11.7% | ||
| Q2 25 | 14.0% | 12.6% | ||
| Q1 25 | -10.2% | 10.9% | ||
| Q4 24 | 9.0% | 16.3% | ||
| Q3 24 | 18.8% | 14.3% | ||
| Q2 24 | 5.8% | 12.4% | ||
| Q1 24 | 7.0% | 6.8% |
净利率MCYRVTY
| Q4 25 | 13.2% | 12.7% | ||
| Q3 25 | 17.7% | 6.7% | ||
| Q2 25 | 11.3% | 7.5% | ||
| Q1 25 | -7.8% | 6.4% | ||
| Q4 24 | 7.4% | 13.0% | ||
| Q3 24 | 15.1% | 13.8% | ||
| Q2 24 | 4.8% | 8.0% | ||
| Q1 24 | 5.8% | 4.0% |
每股收益（稀释后）MCYRVTY
| Q4 25 | $3.66 | $0.86 | ||
| Q3 25 | $5.06 | $0.40 | ||
| Q2 25 | $3.01 | $0.46 | ||
| Q1 25 | $-1.96 | $0.35 | ||
| Q4 24 | $1.82 | $0.77 | ||
| Q3 24 | $4.17 | $0.77 | ||
| Q2 24 | $1.13 | $0.45 | ||
| Q1 24 | $1.33 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | $575.0M | — |
| 股东权益账面价值 | $2.4B | $7.3B |
| 总资产 | $9.6B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.24× | — |
8季度趋势，按日历期对齐
现金及短期投资MCYRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
总债务MCYRVTY
| Q4 25 | $575.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $575.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益MCYRVTY
| Q4 25 | $2.4B | $7.3B | ||
| Q3 25 | $2.2B | $7.4B | ||
| Q2 25 | $2.0B | $7.6B | ||
| Q1 25 | $1.8B | $7.6B | ||
| Q4 24 | $1.9B | $7.7B | ||
| Q3 24 | $1.9B | $7.9B | ||
| Q2 24 | $1.6B | $7.9B | ||
| Q1 24 | $1.6B | $7.8B |
总资产MCYRVTY
| Q4 25 | $9.6B | $12.2B | ||
| Q3 25 | $9.4B | $12.1B | ||
| Q2 25 | $9.1B | $12.4B | ||
| Q1 25 | $9.0B | $12.4B | ||
| Q4 24 | $8.3B | $12.4B | ||
| Q3 24 | $8.2B | $12.8B | ||
| Q2 24 | $7.7B | $13.4B | ||
| Q1 24 | $7.4B | $13.4B |
负债/权益比MCYRVTY
| Q4 25 | 0.24× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.30× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $287.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $273.9M | $161.8M |
| 自由现金流率自由现金流/营收 | 17.8% | 21.0% |
| 资本支出强度资本支出/营收 | 0.9% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.42× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $1.0B | $509.4M |
8季度趋势，按日历期对齐
经营现金流MCYRVTY
| Q4 25 | $287.9M | $182.0M | ||
| Q3 25 | $496.4M | $138.5M | ||
| Q2 25 | $371.6M | $134.3M | ||
| Q1 25 | $-68.7M | $128.2M | ||
| Q4 24 | $248.3M | $174.2M | ||
| Q3 24 | $318.1M | $147.9M | ||
| Q2 24 | $278.0M | $158.6M | ||
| Q1 24 | $192.6M | $147.6M |
自由现金流MCYRVTY
| Q4 25 | $273.9M | $161.8M | ||
| Q3 25 | $479.5M | $120.0M | ||
| Q2 25 | $357.2M | $115.5M | ||
| Q1 25 | $-81.9M | $112.2M | ||
| Q4 24 | $236.0M | $149.8M | ||
| Q3 24 | $306.2M | $125.6M | ||
| Q2 24 | $266.5M | $136.6M | ||
| Q1 24 | $182.4M | $129.7M |
自由现金流率MCYRVTY
| Q4 25 | 17.8% | 21.0% | ||
| Q3 25 | 30.3% | 17.2% | ||
| Q2 25 | 24.2% | 16.0% | ||
| Q1 25 | -5.9% | 16.9% | ||
| Q4 24 | 17.3% | 20.5% | ||
| Q3 24 | 20.0% | 18.4% | ||
| Q2 24 | 20.4% | 19.7% | ||
| Q1 24 | 14.3% | 20.0% |
资本支出强度MCYRVTY
| Q4 25 | 0.9% | 2.6% | ||
| Q3 25 | 1.1% | 2.6% | ||
| Q2 25 | 1.0% | 2.6% | ||
| Q1 25 | 0.9% | 2.4% | ||
| Q4 24 | 0.9% | 3.4% | ||
| Q3 24 | 0.8% | 3.3% | ||
| Q2 24 | 0.9% | 3.2% | ||
| Q1 24 | 0.8% | 2.7% |
现金转化率MCYRVTY
| Q4 25 | 1.42× | 1.85× | ||
| Q3 25 | 1.77× | 2.97× | ||
| Q2 25 | 2.23× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 2.46× | 1.84× | ||
| Q3 24 | 1.38× | 1.57× | ||
| Q2 24 | 4.44× | 2.87× | ||
| Q1 24 | 2.62× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MCY
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
